weSRCH App on Apple

Advaxis doses first patient with ADXS-NEO cancer immunotherapy - Pharmaceutical Business Review

 
 
Advaxis doses first patient with ADXS-NEO cancer immunotherapyPharmaceutical Business ReviewAdvaxis has started a phase 1 trial with the dosing of the first patient with ADXS-NEO, an investigational personalized immunotherapy candidate targeting personal neoantigens found by sequencing a patient's own cancer cells. ADXS-NEO is being evaluated ...
 
Related NewsFeeds

NBCNews.comMultigene test may find risk for heart disease, diabetes and breast cancerNBCNews.comIt is less useful for some of the most common diseases, such as heart disease or diabetes, because they

19 visits

Link between cancer risk, TNF inhibitor use 'cannot be ruled out'HealioAlthough findings suggest that TNF inhibitors are not associated with an increased risk for cancer recurrence in patients

1 visits

WPSI says screen all women annually for urinary incontinenceEurekAlert (press release)TNF inhibitors not associated with increased cancer recurrence in patients with rheumatoid arthritis and a history

2 visits

Health Data ManagementSensors, smartphones headline tech that helps monitor diabetesHealth Data ManagementTechnology is offering new ways to help those with diabetes, or their loved ones, monitor the

2 visits

theperfectinvestor.comRegenerative Medicine Market Expected to Traverse 25.4% CAGR ...Digital JournalDigital Journal is a digital media news network with thousands of Digital Journalists in 200 countr

11 visits

ForbesNigerian Biotech Startup Using Shrimp Shells To Save Food Wins Top PrizeForbesNigerian biotech startup Coating+ is looking to solve three problems. In Nigeria, the aquaculture industry makes up

7 visits

CBS MiamiNew Contact Lenses Could Help Patients With Diabetes Keep Vision LongerCBS MiamiPASADENA (CBAMiami) - Millions of people with diabetes live with the dread of eventually losing their eyesight

1 visits

PharmaLive (press release)Webinar: Humira/Biosimilar developability and preformulation with RALS applicationPharmaLive (press release)When: Thursday, September 6th, 2018 - 2:00 PM EDT. Where: Live on

2 visits

EurekAlert (press release)Hijacking cellular 'mail' for regenerative medicine | EurekAlert ...EurekAlert (press release)University of Illinois at Chicago researchers have received approximatel

2 visits

Synergy Has Turned A CornerSeeking AlphaI was lucky enough to stumble upon Synergy Pharmaceuticals (SGYP) after they had already dropped to around $2/share earlier this year (I could see myself having

2 visits

Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2018PR Newswire (press release)Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company commit

0 visits

Daily Business Report (blog)Global Regenerative Medicine Market Share Sales, Production, And Cost Forecasting Upto 2026Daily Business Report (blog)Global Regenerative Medicine Market 2018 furnish a gr

2 visits

Motley FoolIonis Pharmaceuticals' Royalties Rise, but So Do ExpensesMotley FoolIn the second quarter, Ionis Pharmaceuticals (NASDAQ:IONS) continued bringing in royalties from its spinal muscular a

0 visits

China Biologic Products (NASDAQ:CBPO) Rating Lowered to Neutral at Credit Suisse GroupFairfield CurrentChina Biologic Products (NASDAQ:CBPO) was downgraded by research analysts at Credit Suisse Group

0 visits

Orchard raises $150 million to expandPharmaLive (press release)LONDON (Reuters) - Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy

19 visits

FDA Issues CRL for New Dosing Label for EyleaPharmaLive (press release)Written by: BioSpace | news@biospace.com | Dated: Monday, August 13th, 2018. Regeneron's Eylea Stumbles as FDA Issues CRL for

19 visits

Amicus sets $315000 price for new Fabry disease treatmentPharmaLive (press release)(Reuters) - Amicus Therapeutics (FOLD.O) on Monday set an average price of $315,000 per year for its newly approved F

7 visits

CEO Spills the Secret to Attracting, Retaining Biotech TalentPharmaceutical Executive (press release) (blog)As the CEO of Eloxx Pharmaceuticals, one of my main goals is to attract top talent to our fa

8 visits

Can CGM Be a Game Changer for Pilots With Type 1 Diabetes? Two Men on a Mission Say YesAJMC.com Managed Markets NetworkFor decades, the rules from the Federal Aviation Administration (FAA) and most ot

3 visits

SGLT-2 inhibitors may increase risk for amputation in type 2 diabetesHealioNew users of sodium-glucose cotransporter 2 inhibitors may be more likely to undergo a lower extremity amputation when compar

1 visits